PHYSICAL ACTIVITY IN DAILY LIFE, EXERCISE CAPACITY AND QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE ON INFLIXIMAB-INDUCED REMISSION: A PRELIMINARY STUDY

PHYSICAL ACTIVITY IN DAILY LIFE, EXERCISE CAPACITY AND QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE ON INFLIXIMAB-INDUCED REMISSION: A PRELIMINARY STUDY

ABSTRACT BACKGROUND: Physical activity in daily life and exercise capacity have not been assessed in patients with Crohn’s disease to date. OBJECTIVE: To evaluate the physical activity in daily life, exercise capacity, quality of life, and prevalence of mood disorders in patients with moderate-t...

Full description

Bibliographic Details
Main Authors:	Andrea Lemos CABALZAR, Felipe Meirelles de AZEVEDO, Fernando de Azevedo LUCCA, Maycon de Moura REBOREDO, Carla MALAGUTI, Júlio Maria Fonseca CHEBLI
Format:	Article
Language:	English
Published:	Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE) 2019-10-01
Series:	Arquivos de Gastroenterologia
Subjects:	Crohn disease Exercise tolerance Exercise
Online Access:	http://www.scielo.br/pdf/ag/v56n4/1678-4219-ag-s0004280320190000065.pdf

Similar Items

Infliximab for Anoperineal Lesions in Crohn's Disease: Remission Appears to be Based on Rapid Combination Therapy at High Doses
by: Nadia Fathallah, et al.
Published: (2022-06-01)

Fatal evolution of systemic lupus erythematosus associated with Crohn's disease
by: CHEBLI Júlio M. Fonseca, et al.
Published: (2000-01-01)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016-12-01)

Probiotics in Crohn's disease remission: a systematic review
by: Kamilla Pontes Azevedo, et al.
Published: (2022-03-01)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
by: Luis Eduardo Miani Gomes, et al.
Published: (2019-04-01)

HOW IS THE DIET QUALITY OF PATIENTS WITH CROHN’S DISEASE IN CLINICAL REMISSION USING INFLIXIMAB?
by: Melissa Mercadante Santana CRUZ, et al.
Published: (2021-10-01)

Metastatic Crohn’s disease despite infliximab therapy
by: Sara Campos, et al.
Published: (2017-01-01)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
by: You Lim Kim, et al.
Published: (2014-01-01)

Preoperative respiratory muscle training combined with aerobic exercise improves respiratory vital capacity and daily life activity following surgical treatment for myasthenia gravis
by: Sai Chen, et al.
Published: (2023-04-01)

Predictors of response to infliximab in patients with fistulizing Crohn's disease Factores predictivos de respuesta a infliximab en pacientes con enfermedad de Crohn fistulizante
by: M. Luna-Chadid, et al.
Published: (2004-06-01)

Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients
by: Martyna Szczubełek, et al.
Published: (2021-11-01)

Early intestinal obstruction after infliximab therapy in Crohn’s disease
by: Mitsuro Chiba, et al.
Published: (2019-08-01)

Successful Treatment of Postoperative Fistula with Infliximab in a Patient with Crohn's Disease
by: Seong Yeon Jeong, et al.
Published: (2014-01-01)

Infliximab improves quality of life in the short-term in patients with fistulizing Crohn's disease in clinical practice Infliximab mejora la calidad de vida en pacientes con enfermedad de Crohn fistulosa
by: V. Cadahia, et al.
Published: (2004-06-01)

Adenocarcinoma de recto y ano en paciente con enfermedad de Crohn tratado con infliximab Adenocarcinoma of the rectum and anus in a patient with Crohn´s disease treated with infliximab
by: J. Egea Valenzuela, et al.
Published: (2010-08-01)

Infliximab-induced intertriginous psoriasis in patient with Crohn's desease
by: Federica Mola, et al.
Published: (2011-10-01)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
by: Saeed Razmeh, et al.
Published: (2021-03-01)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
by: Aibar Aginbay, et al.
Published: (2022-11-01)

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
by: Tsutomu Mizoshita, et al.
Published: (2016-06-01)

The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
by: Shuyan Li, et al.
Published: (2023-08-01)

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
by: George Alex, et al.
Published: (2013-10-01)

Association between genetic variants and development of antibodies to infliximab: A cross-sectional study in Chinese patients with Crohn’s disease
by: Kouzhu Zhu, et al.
Published: (2023-01-01)

Tratamento da doença de Crohn com infliximabe: primeira opção? Treatment of Crohn's disease with infliximab: first choice?
by: Anna Paula Rocha Malheiros, et al.
Published: (2009-06-01)

Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
by: Nam Hee Kim, et al.
Published: (2014-10-01)

Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s disease
by: Ye Ma, et al.
Published: (2023-03-01)

Infliximab-induced psoriasis in a patient with crohn′s disease
by: Iqbal Bukhari, et al.
Published: (2015-01-01)

Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab
by: Hye-In Jung, et al.
Published: (2021-01-01)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease
by: Yizhong Wang, et al.
Published: (2021-01-01)

Fitness for life /
by: 327611 Corbin, Charles B., et al.
Published: (2002)

The influence of physiotherapy on the treatment of inflammatory bowel diseases – a short overview
by: Bartłomiej Wrzesiński, et al.
Published: (2018-07-01)

The influence of physiotherapy on the treatment of inflammatory bowel diseases – a short overview
by: Bartłomiej Wrzesiński, et al.
Published: (2018-07-01)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
by: Yiyoung Kwon, et al.
Published: (2022-09-01)

MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease
by: Jing Feng, et al.
Published: (2022-01-01)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
by: Matsumoto S, et al.
Published: (2018-07-01)

Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn’s disease
by: Francisco Guilherme Cancela e Penna, et al.
Published: (2020-02-01)

Health related quality of life in patients with Cohn's disease in remission Calidad de vida en pacientes con enfermedad de Crohn en remisión
by: M. Iglesias, et al.
Published: (2010-11-01)

Non Electrocardiographic alterations in exercise testing in asymptomatic women. Associations with cardiovascular risk factors
by: Ricardo Quental Coutinho, et al.

Closure of enterovesical fistula in Crohn’s disease with infliximab: case report
by: Flávio Steinwurz
Published: (2003-03-01)

A novel role of the splenic volume in Crohn’s disease: evaluating the efficacy of infliximab
by: Xuan Shi, et al.
Published: (2023-08-01)